Aileron Therapeutics Stock News

Palantir Technologies Inc. (NYSE:PLTR) with the stream of 1.18% also noticed, India Aileron Therapeutics, Inc. (NASDAQ:ALRN) encountered a rapid change of 2.34% in the last hour of Wednesdays trading session. The post Featured Volatile Stock: Palantir Technologies Inc. (NYSE:PLTR), Aileron Therapeutics, Inc. (NASDAQ:ALRN) appeared first on Stocks Equity .

Aileron Therapeutics, Inc. (NASDAQ:ALRN) with the stream of -0.83% also noticed, India Tellurian Inc. (AMEX:TELL) encountered a rapid change of -3.39% in the last hour of Tuesdays trading session. Aileron The post Perspiring Stock: Aileron Therapeutics, Inc. (NASDAQ:ALRN), Tellurian Inc. (AMEX:TELL) appeared first on Stocks Equity .

Game Plan Financial Advisors LLC boosted its position in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) by 27.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 127,000 shares of the companys stock after acquiring an additional 27,000 shares during the period. Game Plan []

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Seducing stocks: Twitter, Inc. (NYSE:TWTR 1.62%), Aileron Therapeutics, Inc. (NASDAQ:ALRN -2.78%) appeared first on Stocks Equity .

Aileron Therapeutics, Inc. (ALRN) with the stream of -6.14% also noticed, India PEDEVCO Corp. (PED) encountered a rapid change of -7.89% in the last hour of Mondays trading session. Aileron The post Remarkable Stock Watch Later: Aileron Therapeutics, Inc. (NASDAQ:ALRN), PEDEVCO Corp. (AMEX:PED) appeared first on Stocks Equity .

Jonestrading restated their buy rating on shares of Aileron Therapeutics (NASDAQ:ALRN) in a report published on Thursday morning, Analyst Price Targets reports. Jonestrading currently has a $5.00 price target on the stock. Separately, Zacks Investment Research cut shares of Aileron Therapeutics from a hold rating to a sell rating in a research note on Wednesday, []

Outlook Therapeutics, Inc. (OTLK) with the stream of 7.87% also noticed, India Aileron Therapeutics, Inc. (ALRN) encountered a rapid change of -0.97% in the last hour of trading session. Outlook The post Volume Movers: Outlook Therapeutics, Inc. (NASDAQ:OTLK), Aileron Therapeutics, Inc. (NASDAQ:ALRN) appeared first on Stocks Equity .

Wall Street brokerages expect Aileron Therapeutics, Inc. (NASDAQ:ALRN) to post earnings per share (EPS) of ($0.08) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics posted earnings per share of ($0.12) during the same quarter last year, which would indicate a positive year-over-year growth rate […]

Equities analysts forecast that Aileron Therapeutics, Inc. (NASDAQ:ALRN) will post earnings of ($0.08) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aileron Therapeutics earnings. Aileron Therapeutics reported earnings of ($0.12) per share during the same quarter last year, which would suggest a positive year over year []

Equities analysts expect Aileron Therapeutics, Inc. (NASDAQ:ALRN) to announce ($0.08) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Aileron Therapeutics earnings. Aileron Therapeutics posted earnings per share of ($0.12) in the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The firm []

Aileron Therapeutics (NASDAQ:ALRN) announced its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07), MarketWatch Earnings reports. Shares of ALRN traded down $0.06 during trading hours on Friday, hitting $0.87. The companys stock had a trading volume of 575,635 shares, compared to its average volume []

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's ac

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patie

Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology ( ESMO21 ) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.  Aileron is

BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patie